2-methyl-1-(methylamino)propan-2-ol hydrochloride | 866224-55-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-methyl-1-(methylamino)propan-2-ol hydrochloride
• 英文别名: 2-Methyl-1-(methylamino)-2-propanol hydrochloride；2-methyl-1-(methylamino)propan-2-ol;hydrochloride
• CAS: 866224-55-7
• 化学式: C₅H₁₃NO*ClH
• 分子量: 139.625
• InChiKey: CAIKGAIAASGOOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-methyl-1-(methylamino)propan-2-ol hydrochloride 、 2-(methanesulfonyl)-N-[(5-phenyl-1H-imidazol-2-yl)methyl]-8-(propan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-4-amine 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 以28%的产率得到2-methyl-1-{methyl[4-{[(5-phenyl-1H-imidazol-2-yl)methyl]amino}-8-(propan-2-yl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}propan-2-ol
  参考文献：
  名称：

  [EN] PYRAZOLOTRIAZINES
  [FR] PYRAZOLOTRIAZINES

  摘要：

  本发明提供了具有通用公式（I）的化合物，其中X，R1，R2和R3如本文所述和定义，制备所述化合物的方法，用于制备所述化合物的有用中间化合物，包含所述化合物的药物组合物和组合，以及使用所述化合物用于制造用于治疗和/或预防疾病的药物组合物，特别是作为单一剂或与其他活性成分结合使用的过度增殖障碍，如癌症疾病。

  公开号：

  WO2021116178A1

文献信息

• Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
  申请人：Hashizume Yoshinobu

  公开号：US20070197500A1

  公开（公告）日：2007-08-23

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 independently represent a hydrogen atom or the like; R 3 represents a hydrogen atom, or the like; R 4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R 5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxygen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

  本发明提供了以下化合物的公式(I)、其药学上可接受的酯或其药学上可接受的盐，其中R1和R2独立地表示氢原子或类似物；R3表示氢原子或类似物；R4表示氢原子或类似物；(公式II)代表以下之一或类似物；R5表示具有6至10个环原子的芳基基团或类似物；X表示氧原子或类似物；Y表示氧原子或类似物，n表示整数0、1或2。这些化合物具有ORL1受体拮抗活性；因此，它们对于治疗疾病或症状，如疼痛、各种中枢神经系统疾病等非常有用。
• ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST
  申请人：Pfizer Japan, Inc.

  公开号：EP1732893A2

  公开（公告）日：2006-12-20
• US7354925B2
  申请人：——

  公开号：US7354925B2

  公开（公告）日：2008-04-08
• [EN] ALPHA ARYL OR HETEROARYL METHYL BETA PIPERIDINO PROPANAMIDE COMPOUNDS AS ORL1-RECEPTOR ANTAGONIST<br/>[FR] COMPOSES ALPHA-ARYLE OU HETEROARYLE METHYLE BETA PIPERIDINO PROPANAMIDE EN TANT QU'ANTAGONISTE DU RECEPTEUR ORL1
  申请人：PFIZER JAPAN INC

  公开号：WO2005092858A2

  公开（公告）日：2005-10-06

  This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester of such compound, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom or the like; (formula II) represents one of the following or the like; R5 represents an aryl group having from 6 to 10 ring atoms or the like; X represents an oxygen atom, or the like; Y represents an oxgen atom or the like and n represents an integer 0, 1 or 2. These compounds have ORL1-receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.
• [EN] PYRAZOLOTRIAZINES<br/>[FR] PYRAZOLOTRIAZINES
  申请人：BAYER AG

  公开号：WO2021116178A1

  公开（公告）日：2021-06-17

  The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

  本发明提供了具有通用公式（I）的化合物，其中X，R1，R2和R3如本文所述和定义，制备所述化合物的方法，用于制备所述化合物的有用中间化合物，包含所述化合物的药物组合物和组合，以及使用所述化合物用于制造用于治疗和/或预防疾病的药物组合物，特别是作为单一剂或与其他活性成分结合使用的过度增殖障碍，如癌症疾病。